Healthcare
Galectin Therapeutics Inc.(GALT)
Live Price
Offline$2.80
-1.06% today
1Y Change
+5.18%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $150.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +36.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Galectin Therapeutics Inc. (GALT) is a Healthcare stock with a market cap of $150.00M and listed on NASDAQ. The stock last traded around $2.80 and up 5.2% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +36.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +36.8%, free cash flow +42.8% with operating margin 0.0% and ROIC -174.3%. Stock Foundry combines GALT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +36.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.8% | +0.0% | โ |
2026 Mar 31, 2026 | +20.0% | -3.9% | -20.4% | -19.4% |
2025 Nov 14, 2025 | -18.2% | +8.9% | -2.9% | +18.1% |
Benchmark Edge
GALT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GALT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GALT Max Drawdown
-68.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GALT and SPY.
Company Overview
Galectin Therapeutics Inc.
NASDAQ Capital Market
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Leadership
- Joel Lewis
- IPO Date
- Sep 4, 2002
- Employees
- 15
- Street Address
- 4960 Peachtree Industrial Boulevard
- Mailing
- Norcross, GA, 30071
- Region
- Norcross, GA, US
- Reporting Currency
- USD
- Investor Line
- 678 620 3186
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +36.8%
- Free Cash Flow
- +42.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 25.6%
- ROIC
- -174.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.